Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients

by Doi, T, Takiuchi, H, Ohtsu, A, Fuse, N, Goto, M, Yoshida, M, Dote, N, Kuze, Y, Jinno, F, Fujimoto, M, Takubo, T, Nakayama, N, Tsutsumi, R
Published 2012